This diagnostic tool is designed for the quick detection of specific viral antigens, indicating the presence of SARS-CoV-2 (COVID-19) or influenza A and B viruses. It relies on immunoassay technology to identify these antigens directly from nasal or nasopharyngeal swab samples. The test provides results within a short timeframe, typically under 15 minutes, making it a valuable resource for preliminary screening and point-of-care testing.
Timely identification of respiratory infections is crucial for implementing appropriate infection control measures, guiding treatment decisions, and mitigating the spread of illness within communities. The accessibility and speed of this type of assay allows for rapid triage in various settings, including hospitals, clinics, schools, and workplaces. Early detection of influenza or COVID-19 can lead to quicker initiation of antiviral therapy (where appropriate), isolation procedures, and public health interventions. Historically, the availability of rapid antigen tests has proven instrumental during periods of heightened viral transmission.
